• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Gilead Capital

BioCentury | Dec 10, 2024
Deals

Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar

Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Mar 2, 2022
Product Development

March 1 Quick Takes: Setbacks in C. diff for Pfizer, Finch

Plus Karyopharm tumbles, Epizyme cuts, and updates from Alnylam, Novavax, Gilead and more
BioCentury | Feb 1, 2022
Data Byte

At least seven PDUFA dates on deck in February

Five submissions under FDA priority review
Items per page:
1 - 3 of 3